Hansa Biopharma - Sales support, easing funding pressure and a strategic review

Hansa continues to progress, and despite a slower period in Germany, the H1 2025 sales growth is now 52% with a positive outlook that will improve further with US support and normalised German demand.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/